NCT04992988

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Cancer Hospital of Guangxi Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single-arm, phase II trial to study the efficacy of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy in treating patients with locoregionally recurrent nasopharyngeal carcinoma.

Conditions

• Nasopharyngeal Carcinoma
• Toripalimab
• Recurrent Nasopharyngeal Squamous Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Toripalimab	Toripalimab 240mg every 3 weeks with a total of 3 cycles as concurrent anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 9 cycles as adjuvant anti-PD-1 immunotherapy 2 weeks after CCRT

Timeline

• Start date: 2020-06-28
• Primary completion: 2022-06-01
• Completion: 2022-06-01
• First posted: 2021-08-06
• Last updated: 2021-08-20

Locations

1 site across 1 country: China